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Abstract: Elevated plasma levels of homocysteine (Hcy), known as hyperhomocysteinemia 
(HHcy), are associated with osteoporosis. A decrease in bone blood flow is a potential cause 
of compromised bone mechanical properties. Therefore, we hypothesized that HHcy decreases 
bone blood flow and biomechanical properties. To test this hypothesis, male Sprague–Dawley 
rats were treated with Hcy (0.67 g/L) in drinking water for 8 weeks. Age-matched rats served 
as controls. At the end of the treatment period, the rats were anesthetized. Blood samples were 
collected from experimental or control rats. Biochemical turnover markers (body weight, Hcy, 
vitamin B12, and folate) were measured. Systolic blood pressure was measured from the right 
carotid artery. Tibia blood flow was measured by laser Doppler flow probe. The results indicated 
that Hcy levels were significantly higher in the Hcy-treated group than in control rats, whereas 
vitamin B12 levels were lower in the Hcy-treated group compared with control rats. There was 
no significant difference in folate concentration and blood pressure in Hcy-treated versus con-
trol rats. The tibial blood flow index of the control group was significantly higher (0.78 ± 0.09 
flow unit) compared with the Hcy-treated group (0.51 ± 0.09). The tibial mass was 1.1 ± 0.1 g 
in the control group and 0.9 ± 0.1 in the Hcy-treated group. The tibia bone density was unchanged 
in Hcy-treated rats. These results suggest that Hcy causes a reduction in bone blood flow, which 
contributes to compromised bone biomechanical properties.
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Introduction
Osteoporosis is a pathological condition whereby the skeleton undergoes remodeling 
and reduction in bone density (BD).1,2 Osteoporosis is a very prevalent disease that 
affects more than 75 million people in Europe, the US, and Japan.1 It has a widespread 
social and economic impact in the global population, costing US$16.9 billion in the 
US alone.3 Over 10 years, postmenopausal women in the US experienced 5.2 million 
fractures of the hip, spine, or forearm, which is equivalent to 2 million years with a 
disability.4 Hence, identifying factors involved in this process, aside from low   vitamin D 
and calcium intake,5 becomes paramount in our investigation.
Homocysteine (Hcy) is a sulfur-containing, nonproteinogenic amino acid formed 
during the metabolism of methionine.6 Elevated levels of total plasma Hcy are known 
as hyperhomocysteinemia (HHcy). Recently, increased plasma Hcy has been suggested 
to be an independent risk factor for osteoporosis and bone quality.7,8 In addition, HHcy 
is accompanied by disruption of biochemical bone turnover markers, osteocalcin, and 
collagen I C-terminal cross-laps.9 However, the mechanistic role of Hcy in osteoporosis 
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HHcy-induced oxidative stress may occur as a consequence 
of either decreased expression or activity of key antioxidant 
enzymes or increased enzymatic generation of superoxide 
anions.10 Superoxide anions may react with nitric oxide (NO) 
to produce peroxynitrite with reduced NO bioavailability,11 
which may impair the osteoblast–osteoclast balance, with 
unpredictable consequences on bone remodeling. An increase 
in oxidative stress, which leads to reduce NO bioavailability, 
decreases bone blood flow and hence leads to osteoporosis.12
Blood flow is essential for normal bone growth and bone 
repair.13 Therefore, inadequate blood flow to skeletal struc-
tures could impair normal development and/or the healing 
process of bone. The two most essential factors in bone heal-
ing are stabilization of the osseous fragments and blood flow. 
After a bone fracture, blood flow to the injury site changes 
to meet the metabolic needs of the healing tissue.13
Several previous studies have shown that HHcy alters 
the ability of vasculature to dilate because it decreases 
NO bioavailability, which increases vascular resistance.14 
Considering the convincing studies in which HHcy resulted 
in increased vascular resistance, we proposed that HHcy rats 
would have decreased bone blood flow as a consequence of 
this, thereby altering biomechanical properties such as den-
sity and net weight.
Materials and methods
induction of HHcy
Male Sprague–Dawley rats, 8 weeks of age (250–300 g), were 
kept in cages at room temperature under a day/night rhythm 
and fed a standard laboratory chow. The rats were divided into 
a wild-type group (n = 10) and an HHcy group (n = 12), both 
groups receiving an identical diet. In accordance with previous 
studies, to create a condition of mild HHcy, Hcy was supple-
mented (0.67 g dl-Hcy [Sigma H-4628; Sigma-Aldrich, 
St Louis, MO, USA]/L drinking water) for 8–12 weeks. The 
low Hcy diet was selected because studies on rats had illus-
trated that this dose-induced mild HHcy was well tolerated.14 
Control rats received Hcy-free water. The animals were 
killed with sodium pentobarbital (70 mg/kg) at the end of 
the experiments. All animal procedures were performed in 
accordance with National Institutes of Health guidelines for 
animal research and were reviewed and approved by the 
  University of Louisville Animal Care and Use Committee.
Measurement of plasma Hcy
Blood samples were collected after an overnight fast. The 
samples were stored at −80°C until the day of analysis. 
Plasma was used to detect the concentrations of Hcy by 
high-pressure liquid chromatography, vitamin B12, and folate 
as described previously.9,15
In vivo bone blood flow measurement
Bone blood flow was measured as described previously.13 
On the day of the bone blood flow measurement experiment, 
the rats were anesthetized. Body temperature was maintained 
between 37°C and 39°C using a heating pad. The left carotid 
artery was cannulated to measure arterial blood pressure. 
The left tibia was exposed at a midshaft position by surgical 
incision, and 5 mM of soft tissue and periosteum were 
removed to expose the cortex. A laser Doppler flow meter 
was used to assess bone blood flow. The flow probe was 
positioned along the anteromedial surface of the tibia. 
  Estimates of flow were obtained every 3–4 sec over a period 
of 4–6 min. At the conclusion of the experiment, the tibia 
was excised and weighed.
Measurement of BD
The apparent BD was determined by the Archimedes 
  principle to decide whether there was a change in bone 
mechanical properties.
Other measures
Height and weight were measured by scale, and tibia mass 
index was calculated as weight in kilograms divided by the 
square of height in meters.
statistical analysis
Values are reported as mean ± standard error of the mean in 
all four groups. Differences between groups were tested by 
two-way analysis of variance. Tukey’s multiple comparison 
test was used to compare group means, and results were 
considered significant if P , 0.05.
Results
There was no significant difference in initial body weights 
of control (208 ± 0.01) and Hcy-treated (238.1 ± 0.03) rats 
(Table 1). As expected, plasma Hcy concentrations were 
significantly increased in the Hcy-treated group (17.2 ± 
9 µmol/L) compared with the control group (3.0 ± 5 µmol/L). 
Serum folate concentration was similar in both groups 
(35.5 ± 4.2 nmol/L in the HHcy group and 32.5 ± 4.7 nmol/L 
in the control group), whereas vitamin B12 was significantly 
lower in the HHcy group (338 ± 49 pmol/L) compared 
with the control group (450 ± 85 pmol/L). The tibial mass 
was 1.1 ± 0.1 g in the control group and 0.9 ± 0.1 g in the 
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The bone blood flow index was reduced in Hcy- 
treated rats. Blood flow to the tibia of control rats (0.78 ± 
0.09 units, n = 5) was significantly higher than the blood flow 
to the tibia of Hcy-treated rats (0.51 ± 0.09 units, n = 5) 
(Figure 1).
There was no difference in right tibia wet weight in Hcy-
treated rats (0.3 g, n = 3). There was no difference in the wet 
tibia weight for control and Hcy-treated rats (n = 5) 
(Figure 2).
The tibia BD was unchanged in Hcy-treated rats. The 
densities of the tibias from control and Hcy-treated rats 
  suggested no difference (1.6 g/cm3, n = 5) (Figure 3).
Discussion
The present study clearly demonstrated that there was a 
significant decrease in bone blood flow in Hcy-treated rat 
tibia versus control rat tibia (Figure 1). This result was 
  consistent with our plethora of evidence that indicated Hcy 
had some role in modulating those systems involved in 
vasodilation both in vivo and in vitro. A study in humans 
showed that high plasma Hcy level was independently 
associated with greater brachial-ankle pulse wave 
velocity.16
Kumar et al showed decreased carotid artery blood flow 
in heterozygote cystathionine β-synthase mice (CBS+/−, 
genetically HHcy mice).17 Elevated plasma levels of Hcy 
in these mice (CBS+/−) caused an increase in arterial 
  remodeling, in part due to an increase in the collagen/elastin 
ratio, resulting in amplified vascular resistance, and led to a 
measured decrease in carotid artery blood flow.17 One pos-
sible mechanism for this was that Hcy caused oxidative stress 
that led to the activation of matrix metalloproteinase in the 
extracellular matrix.
In concordance with those studies, another study showed 
that HHcy impaired angiogenesis in a murine model of limb 
ischemia. This could have resulted in greater vascular resis-
tance and decreased bone blood flow.18 Riza Erbay et al 
showed that patients with slow coronary flow had high level 
of plasma Hcy compared with patients with normal coronary 
flow; this study suggested a correlation between high Hcy 
Table  1  Biochemical  findings  in  animals  at  the  end  of  the 
treatment period
Control Experimental group
Body weight 208 ± 0.01 238 ± 0.03
Homocysteine, µmol/L 3.0 ± 5 17.20 ± 9*
Folic acid, nmol/L 35.5 ± 4.2 32.5 ± 4.7
Vitamin B12, pmol/L 450 ± 85 338 ± 49*
Note: *P , 0.05 versus control.
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Figure 1 Flow index was reduced in Hcy-treated rats. Blood flow to the tibia 
of control rats (0.78 ± 0.09 units) was significantly higher than blood flow to the 
Hcy-treated rats (0.51 ± 0.09 units).
Note: *P , 0.05 compared with control.
Abbreviation: Hcy, homocysteine.
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Figure 2 no difference was observed in right tibia wet weight in Hcy-treated rats. 
There was no difference in the tibia wet weight between control and Hcy-treated 
rats.
Abbreviation: Hcy, homocysteine.
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Figure 3 Density was unchanged in Hcy-treated rats. The density of the tibias 
between control and Hcy-treated rats suggested no difference.
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and coronary flow and a possible role in the pathogenesis of 
impaired flow.19
Hence, we clearly see a role of Hcy in modulating bone 
blood flow in a variety of contexts and experimental models. 
Our results have provided yet another context and model by 
which Hcy alters bone blood flow. The pathological conse-
quences of this remain to be elucidated.
We proposed that there would be a decrease in BD in the 
Hcy-treated group of rats. However, we did not note any 
changes in density or dry or wet weight of tibia among the 
Hcy group versus control rats (Figures 2 and 3).   However, 
BD is not the only clinically important value in determining 
susceptibility to fracture; in fact, many studies have noted 
bone quality as a major risk factor for fracture, with   differences 
in the following measures: geometry, bone mass   distribution, 
trabecular bone architecture, microdamage, remodeling activ-
ity, bone mineral, and matrix tissue properties.20–22 Therefore, 
although BD did not decrease under our experimental condi-
tions, there could   possibly have been a change in bone quality. 
However, we did not perform these measures, and this is war-
ranted for future study.
Both folate and vitamin B12 are cofactors of the methion-
ine synthase reaction and play an important role in Hcy 
metabolism.6 The consumption of folate and vitamin B12 is 
high in the presence of high Hcy concentrations in plasma. 
In the present study, serum vitamin B12 concentration 
was   significantly lower in the Hcy-treated group compared 
with control rats; however, there was no significant change 
in folate concentration. As vitamin B12 and folate are 
directly involved in the regulation of Hcy concentrations in 
blood, the question arises whether a reduction in concen-
trations of these vitamins has any effect on biochemical 
markers of bone. Carmel et al demonstrated reductions in 
biochemical markers (osteocalcin) in vitamin B12-deficient 
individuals.23
Mice treated with folate antagonist showed reduced bone 
growth,24 and this was further supported by data suggesting 
that folate may have significant effects on bone that are 
independent of Hcy.25 In contrast, recently, other studies have 
shown that folate supplementation does not affect biochemi-
cal markers of bone turnover, although it decreases Hcy 
concentrations in healthy subjects.26
Overall hypothesis
HHcy
ROS
NO
Endothelial vasodilation
Bone blood flow
Bone biomechanical properties
Osteoporosis
Control tibia High Hcy tibia
Figure 4 The hypothesis was that high levels of Hcy lead to increased ROs, decreased nO bioavailability and other factors, decreased endothelial vasodilation, and decreased 
bone blood flow, which could lead to decreased biomechanical properties. The hypothesis was that high levels of Hcy lead to increased vascular resistance from decreased 
vasodilation, which could lead to decreased biomechanical properties, including decreased BD.
Abbreviations: HHcy, hyperhomocysteinemia; Hcy, homocysteine; nO, nitric oxide; ROs, reactive oxygen species.Vascular Health and Risk Management
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We found no difference in weight and density, so there may 
be some compensatory mechanism. Further studies are 
required. A longer exposure to Hcy or a higher plasma level 
could further reduce bone blood flow and potentially compro-
mise bone mechanical properties, as suggested in human 
studies. Previous evidence from our laboratory suggested 
that Hcy increased oxidative stress and decreased the bioavail-
ability of NO, an important dilator of the bone vasculature, and 
hence supports the hypothesis presented in Figure 4. In sum-
mary, the present study provides strong evidence that HHcy is 
a major cause of weakening of the bone. Future studies are 
required to clarify the mechanisms of the HHcy effect.
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